SCHEMBL4639739

SCHEMBL4639739

CCCn1c(=O)c2[nH]c(-c3c[nH]nc3Cc3cccc(OC(=O)O)n3)nc2n(CCC)c1=O

nearest known ligand 0.52

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
ADORA2B P29275 15/20 0.52
ADORA1 P30542 4/20 0.51
ADORA2A P29274 10/20 0.51
KDM4E B2RXH2 1/20 0.50
MEN1 O00255 1/20 0.50
ALDH1A1 P00352 1/20 0.50
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50
KMT2A Q03164 1/20 0.50
HSD17B10 Q99714 1/20 0.50
ADORA3 P0DMS8 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL243345 0.88 ADORA2B (0.54) ADORA2BADORA1ADORA2AKDM4EMEN1
SCHEMBL4176128 0.82 ADORA2B (0.62) ADORA2BADORA1ADORA2AKDM4EMEN1
SCHEMBL242409 0.80 ADORA2B (0.56) ADORA2BADORA1ADORA2AKDM4EMEN1
SCHEMBL1947253 0.80 ADORA2B (0.61) ADORA2BADORA1ADORA2AKDM4EMEN1
SCHEMBL4291542 0.80 ADORA2B (0.66) ADORA2BADORA1ADORA2AKDM4EMEN1
SCHEMBL5687959 0.78 ADORA2B (0.63) ADORA2BADORA1ADORA2AKDM4EMEN1
SCHEMBL3466506 0.77 ADORA2B (0.59) ADORA2BADORA1ADORA2AKDM4EMEN1
SCHEMBL1944482 0.77 ADORA2B (0.52) ADORA2BADORA1ADORA2AADORA3
SCHEMBL3466575 0.77 ADORA2B (0.61) ADORA2BADORA1ADORA2AKDM4EMEN1
SCHEMBL5685513 0.77 ADORA2B (0.59) ADORA2BADORA1ADORA2AKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1789053-B1 METHOD OF WOUND HEALING USING A2B ADENOSINE RECEPTOR ANTAGONISTS GILEAD SCIENCES INC (US) 2012-06-13 EP claimed
EP-1622908-B1 XANTHINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS INC (US) 2008-08-06 EP claimed